Your browser doesn't support javascript.
loading
Recombinant Zoster Vaccine (Shingrix): Real-World Effectiveness in the First 2 Years Post-Licensure.
Izurieta, Hector S; Wu, Xiyuan; Forshee, Richard; Lu, Yun; Sung, Heng-Ming; Agger, Paula Ehrlich; Chillarige, Yoganand; Link-Gelles, Ruth; Lufkin, Bradley; Wernecke, Michael; MaCurdy, Thomas E; Kelman, Jeffrey; Dooling, Kathleen.
Afiliação
  • Izurieta HS; Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.
  • Wu X; Acumen LLC, Burlingame, California, USA.
  • Forshee R; Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.
  • Lu Y; Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.
  • Sung HM; Acumen LLC, Burlingame, California, USA.
  • Agger PE; Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.
  • Chillarige Y; Acumen LLC, Burlingame, California, USA.
  • Link-Gelles R; Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Lufkin B; Acumen LLC, Burlingame, California, USA.
  • Wernecke M; Acumen LLC, Burlingame, California, USA.
  • MaCurdy TE; Acumen LLC, Burlingame, California, USA.
  • Kelman J; Centers for Medicare & Medicaid Services, Washington, DC, USA.
  • Dooling K; Centers for Medicare & Medicaid Services, Washington, DC, USA.
Clin Infect Dis ; 73(6): 941-948, 2021 09 15.
Article em En | MEDLINE | ID: mdl-33580242

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neuralgia Pós-Herpética / Vacina contra Herpes Zoster / Herpes Zoster Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neuralgia Pós-Herpética / Vacina contra Herpes Zoster / Herpes Zoster Idioma: En Ano de publicação: 2021 Tipo de documento: Article